Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis

Abstract

Infections and inflammatory processes have been associated with the development of schizophrenia and affective disorders; however, no study has yet systematically reviewed all available studies on cerebrospinal fluid (CSF) immune alterations. We aimed to systematically review the CSF immunological findings in schizophrenia spectrum and affective disorders. We identified all studies investigating CSF inflammatory markers in persons with schizophrenia or affective disorders published prior to March 23, 2017 searching PubMed, CENTRAL, EMBASE, Psychinfo, and LILACS. Literature search, data extraction and bias assessment were performed by two independent reviewers. Meta-analyses with standardized mean difference (SMD) including 95% confidence intervals (CI) were performed on case-healthy control studies. We identified 112 CSF studies published between 1942-2016, and 32 case-healthy control studies could be included in meta-analyses. Studies varied regarding gender distribution, age, disease duration, treatment, investigated biomarkers, and whether recruitment happened consecutively or based on clinical indication. The CSF/serum albumin ratio was increased in schizophrenia (1 study [54 patients]; SMD = 0.62; 95% CI 0.24-1.00) and affective disorders (4 studies [302 patients]; SMD = 0.43; 95% CI 0.25-0.61, I = 0%), compared to healthy controls. Total CSF protein was elevated in both schizophrenia (3 studies [97 patients]; SMD = 0.38; 95% CI 0.12-0.65, I = 0%) and affective disorders (2 studies [53 patients]; SMD = 0.77; 95% CI 0.36-1.18, I = 0%). The IgG ratio was increased in schizophrenia (1 study [54 patients]; SMD = 0.60; 95% CI 0.23-0.98), whereas the IgG Albumin ratio was decreased (1 study [32 patients]; SMD = -0.62; 95%CI -1.13 to -0.12). Interleukin-6 (IL-6) levels (7 studies [230 patients]; SMD = 0.38; 95% CI 0.02-0.74; I = 64%) and IL-8 levels (3 studies [95 patients]; SMD = 0.46; 95% CI 0.17-0.75, I = 0%) were increased in schizophrenia but not significantly increased in affective disorders. Most of the remaining inflammatory markers were not significantly different compared to healthy controls in the meta-analyses. However, in the studies which did not include healthy controls, CSF abnormalities were more common, and two studies found CSF dependent re-diagnosis in 3.2-6%. Current findings suggest that schizophrenia and affective disorders may have CSF abnormalities including signs of blood-brain barrier impairment and inflammation. However, the available evidence does not allow any firm conclusion since all studies showed at least some degree of bias and vastly lacked inclusion of confounding factors. Moreover, only few studies investigated the same parameters with healthy controls and high-quality longitudinal CSF studies are lacking, including impact of psychotropic medications, lifestyle factors and potential benefits of anti-inflammatory treatment in subgroups with CSF inflammation.

Diagnosing Organic Causes of Schizophrenia Spectrum Disorders: Findings from a One-Year Cohort of the Freiburg Diagnostic Protocol in Psychosis (FDPP)

“…WBC counts correlated with IRDA/IRDA rates in EEGs. While inflammatory change frequency was lower than in previous studies, the frequency of disturbed blood-brain barrier parameters was previously described with similar figures [14,46,47]. The blood-brain dysfunction's role in the pathophysiology of schizophreniform psychosis is currently under intense discussion (see [48,49]).…”

Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets

“…Cytokines generated in these responses regulate cell-mediated immunity and phagocytic-dependent inflammation in response to intracellular parasites and can promote autoimmunity (Calcagni & Elenkov, 2006). While the variance in the magnitude and types of overexpressed cytokines can be significant between trials and results can conflict (Orlovska-Waast et al, 2018), a set of cytokines including IL-1β, TNF-α, IL-6, IL-18, IL-17A, and IL-10 do exhibit consistent up regulation in the plasma of untreated MDD patients (Hodes, Kana, Menard, Merad, & Russo, 2015;Syed et al, 2018). Similar alterations in the concentration of these cytokines are noted in their CSF (Young, Bruno, & Pomara, 2014).…”

A prospective three-year follow-up study on the clinical significance of anti-neuronal antibodies in acute psychiatric disorders

“…So, to asses a blood brain barrier dysfunction or intrathecal antibody production in the acute phase was not possible in this study. Hence, prospective, longitudinal, controlled CSF studies in patients with severe psychiatric disorders are needed to further investigate the clinical significance of such findings in subgroups of patients 20 .…”